Cholesterol & Dementia - The lesson from Mendelian Randomization
People born with genes that affect the same cholesterol pathways as statins and ezetimibe have dramatically lower risk of dementia.
Mendelian randomization studies— like the recent landmark study led by Nordestgaard and colleagues described in this video— provide pivotal epidemiological evidence for this:
▶Video · YouTube · DrApoE4This Cholesterol Pathway Cut Dementia Risk by 82% | 1 Million Person StudyIn this video, Dr. Fraser reviews a major 2025 study involving more than 1 million participants that offers powerful new insight into how lifelong cholesterol levels may influence the risk of dementia. Using a genetic research method known as Mendelian randomization, the study examined individuals who inherit genetic variants that naturally lower…youtu.be
Paper · Alzheimers Dement · 2025Cholesterol-lowering drug targets reduce risk of dementia: Mendelian randomization and meta-analyses of 1 million individuals.We tested whether genetically proxied non-high-density lipoprotein cholesterol (non-HDL-C)-lowering drug targets reduce risk of all-cause dementia. We included 1,091,775 individuals from three prospective general population cohorts with individual-level data and two consortia with summary-level data. We selected genetic variants within HMGCR, NPC1L1, PCSK9, ANGPTL4, LPL, and CETP associated with non-HDL-C. These…pmc.ncbi.nlm.nih.gov
In this study, lifelong exposure to lower LDL (and other ApoB particles) via gene variants that mimic the biological effects of statins and ezetimibe was associated with a 76% and 82% reduction in dementia, respectively, for every ~40mg/dL drop in non-HDL cholesterol.
(You can calculate your non-HDL cholesterol by the formula non-HDL = LDL+TG/5.)
Gene variants related to CETP inhibition also showed a 70% reduction in dementia per ~40mg/dL decline in non-HDL cholesterol. (This CETP pathway is targeted by the new cholesterol drug obicetrapib, which is being studied for both CVD and Alzheimer’s.)
But gene variants related to PCSK9 inhibition showed no benefit.
Overall, these findings provide significant empirical support for the hypothesis that long-term, lifelong management of ApoB-containing lipoproteins is neuroprotective.
Randomized trials typically evaluate 3- to 5-year interventions initiated in late adulthood. By the time a 70-year-old participant begins lipid-lowering therapy in a clinical trial, subclinical cerebrovascular injury, amyloid deposition, and microglial activation may have been compounding for decades. A short-term intervention cannot reasonably be expected to reverse established neurodegenerative pathology.
In contrast, Mendelian randomization acts as a natural, lifelong trial. Genetic variants reduce cholesterol exposure from birth, measuring the cumulative "area under the curve" (AUC) of low atherogenic particle exposure across 70 or more years.
Preventing the inception of pathology over a lifetime yields much larger protective dividends compared to mitigating advanced disease late in life.
Furthermore, genetic epidemiology (Mendellian randomization) inherently overcomes the methodological limitations that obscure late-life trial data, such as reverse causality.
In the years preceding an overt dementia diagnosis, prodromal neurodegeneration frequently causes systemic metabolic shifts, weight loss, and an insidious secondary decline in serum cholesterol levels. In observational settings or late-life trials, this phenomenon creates a misleading association between low cholesterol and increased cognitive decline. Because genetic alleles are fixed at conception, Mendelian randomization remains immune to reverse causation, isolating the true causal vector of lower non-HDL cholesterol (LDL + TG/5).
The biological mechanisms underlying this lifelong protection are rooted in the preservation of cerebral vascular integrity.
Lowering circulating non-HDL cholesterol protects penetrating arteriole walls against hypercholesterolemia-induced endothelial dysfunction, arteriolosclerosis, and microinfarcts. Maintaining healthy microvasculature preserves white matter tract architecture and ensures adequate cerebral perfusion.
Moreover, structural integrity of the blood-brain barrier (BBB) is critical for proper glymphatic clearance—the perivascular flushing system responsible for clearing neurotoxic proteins like amyloid-beta and tau. By shielding the cerebral endothelium from lifelong lipotoxicity, low systemic ApoB maintains BBB permeability control and robust waste clearance mechanisms.
The distinct protective signals observed in both HMGCR (statin) and NPC1L1 (ezetimibe) proxies also highlight the value of multi-pathway lipid management.
While statins target hepatic cholesterol synthesis, ezetimibe inhibits intestinal cholesterol absorption. The fact that genetic proxies for NPC1L1 inhibition mirror—and even slightly exceed—the protective magnitude of HMGCR proxies demonstrates that suppressing systemic atherogenic lipoprotein burden through multiple complementary mechanisms confers robust neuroprotection.
Ultimately, these findings shift the paradigm of dementia prevention from late-life rescue to early, lifelong risk modulation. While starting a lipid-lowering agent at age 75 will not instantly yield an 80% reduction in dementia risk, the genetic evidence proves that keeping atherogenic lipoproteins low starting in young adulthood and midlife profoundly alters the trajectory of cognitive aging.
Lifelong lipid optimization represents not merely a cardiovascular strategy, but a core pillar of long-term neurovascular resilience.
This post was written in collaboration with Gemini AI.
#statinsdementiaHD #ezetimibedementiaHD #pcsk9dementiaHD #statinsHD #ezetimibeHD #pcsk9HD #cetpinhibitorHD #obicetrapibHD #dementiaHD #alzheimersHD

